Biotech drug discovery firm Mindset Pharma Inc. (OTCQB: MSSTF) develops next-generation psychedelic and non-psychedelic medicines for neuropsychiatric and neurological disorders. To pursue their goal it received scientific advice from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on several matters regarding the concretion of its first Phase 1 clinical trial plan evaluating the company’s lead psychedelic drug candidate, MSP-1014, for the treatment of major depressive disorder.

The meeting between the MHRA and Mindset focused on discussing the company’s plans for the Phase 1 trial of their second-generation psilocybin-like compound, to be developed in collaboration with specialized UK-based …

Full story available on Benzinga.com